retatrutide clinical trial dose retatrutide Dosage for Weight Loss (Chart Included) retatrutide safety clinical trials A

The primary risk factors include: Chronic constipation and straining during bowel movements Prolonged sitting on the toilet Diarrhoea (less commonly, but repeated episodes can contribute) Increased intra-abdominal pressure Given that Wegovy causes constipation in approximately 24% of users, patients who develop this side effect may experience harder stools and increased straining during defecation

This drug increased the half-life from minutes to 13 hours, thus requiring only one injection daily

* Clinicians prescribing GLP-1s for #obesity management should focus on and help mitigate these challenges by developing care plans that include thorough #nutritional and #lifestyle #counseling before, during, and after the weight reduction period

STEP and SURMOUNT collected adverse event data but didnt systematically track menstrual changes